Proteomics

Dataset Information

0

A degron blocking strategy towards improved CRBN recruiting PROTAC selectivity

ABSTRACT: The different layers of complexity in PROTAC design have slowed the broad implementation of this novel pharmacological approach. Given the challenges and opportunities of CRL4CRBN hijacking PROTACs we set out to identify and develop broadly implementable strategies to generate PROTACs with improved specificity for their targets. We used structural analysis of known neo-substrate degrons to generate “degron blocked IMiD” analogues and validated that they did not degrade any known neo-substrates using quantitative proteomics. We then applied this strategy to a known BRD9 PROTAC (dBRD9-A) to generate a degron-blocking analogue with a specific degradation profile.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Fernando J. Sialana  

LAB HEAD: Jyoti S. Choudhary

PROVIDER: PXD038298 | Pride | 2023-07-10

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20190215_AS_Chopra_lab_LMS2_set14_.msf Msf
20190215_AS_Chopra_lab_LMS2_set14_.pdResult Other
20190215_AS_Chopra_lab_LMS2_set14_01.raw Raw
20190215_AS_Chopra_lab_LMS2_set14_02.raw Raw
20190215_AS_Chopra_lab_LMS2_set14_03.raw Raw
Items per page:
1 - 5 of 63
altmetric image

Publications

Small molecules inducing protein degradation are important pharmacological tools to interrogate complex biology and are rapidly translating into clinical agents. However, to fully realise the potential of these molecules, selectivity remains a limiting challenge. Herein, we addressed the issue of selectivity in the design of CRL4<sup>CRBN</sup> recruiting PROteolysis TArgeting Chimeras (PROTACs). Thalidomide derivatives used to generate CRL4<sup>CRBN</sup> recruiting PROTACs have well described  ...[more]

Similar Datasets

Proteomics A degron blocking strategy towards improved CRBN recruiting PROTAC selectivity
2023-07-10 | PXD038503 | Pride
Proteomics iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
2023-06-27 | PXD038299 | Pride
Proteomics Regulation of eDHFR-tagged proteins with trimethoprim PROTACs
2023-12-06 | PXD045052 | Pride
Proteomics DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
2023-12-18 | PXD046286 | Pride
Proteomics AP-PROTAC-2: a Photoswitchable multi-kinase PROTAC
2022-09-14 | PXD036224 | Pride
Proteomics DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
2023-12-18 | PXD047347 | Pride
Proteomics Redirecting the neo-substrate specificity of Cereblon-targeting PROTACs to Helios
2022-09-07 | PXD036170 | Pride
Proteomics A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogeniccell death
2024-05-23 | PXD043560 | Pride
Proteomics Modeling CRL4A ligase complex to predict target protein ubiquitination induced by CRBN-recruiting PROTACs
2022-05-19 | PXD030213 | Pride
Transcriptomics A potent and selective small-molecule degrader of ENL suppresses leukemia progression in vivo (RNA-Seq)
2024-09-13 | GSE245926 | GEO